SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

BioPharmX Corp. (BPMX)

Add BPMX Price Alert      Hide Sticky   Hide Intro
Moderator: Makin Millions, Whos_Who
Search This Board: 
Last Post: 4/29/2017 11:49:50 AM - Followers: 43 - Board type: Free - Posts Today: 1


Biodelivery that makes a difference! 

We develop unique health and wellness products for licensing and commercialization in pharmaceutical and over-the-counter use.



By design, BioPharmX's innovative drug delivery products, with their unique patented platform technologies, are formulated to address the needs of well-defined, fast-growing, multi-billion dollar markets, including dermatology, aesthetics, otolaryngology (ears, nose & throat), and women’s health.

BioPharmX currently has multiple products in various stages of development in all three of these markets, but its first commercialized product will be a woman’s breast health product launching in January 2015.


  Delivery Pathways

  BioPharmX creates unique drug delivery products for IP licensing or direct commercialization for pharmaceutical, over-the-counter, and supplement distribution and sales.

Product Types

Our unique health and wellness products (for licensing and commercialization in pharmaceutical and over-the-counter (OTC) use) leverage our extensive experience in pharmacological and biological sciences and drug delivery product development. Our team is experienced in performing pre-clinical studies focused on analytics, pharmacokinetics and toxicology, experimental design, and investigational protocols. We do this through product research and development and through strategic partnerships with leading worldwide pharmaceutical companies.

Our commitment to providing customers with products that improve the quality of their lives can only be met through unrivaled innovation and a dedication to quality—both of which are integral parts of BioPharmX's company culture.


            Over the Counter Products        


With significant investments in R&D and a deep background in pharmaceutical and medical device development, BioPharmX is uniquely positioned to bring leading-edge, over-the-counter (OTC) products to the retail marketplace. Our products all meet rigorous internal quality measurements and leverage the capabilities required for pharmaceutical grade FDA products. 


BioPharmX enables innovative solutions by working with pharmaceutical companies worldwide to achieve shorter time-to-market scenarios. We do this through a suite of core competencies unique to our teams:

♦ Customized solutions to fit drug formulation needs
♦ Expertise in regulatory, toxicology and clinical studies
♦ Streamlined pathways through development
♦ Unrivaled commitment to quality





BioPharmX currently has multiple products in various stages of development for therapeutic drug delivery in the areas of women's health, dermatology, aesthetics and ENT.




Our R&D team specializes in developing world-class clinical studies. They perform formulation development, outline safety profiles and dosing requirements, and set validation protocols. Currently they are developing a portfolio of patented drug applications (including novel formulations and minimally invasive delivery devices in respective markets) to be out-licensed or commercialized.


"Biopharmx's first product violet will hit market this fall"
"This company is a $$ maker." 




BioPharmX partners with leading pharmaceutical companies through regulatory approval or performs all activities internally, utilizing our team of regulatory and product development experts. Our partners turn to us to enhance delivery characteristics to improve drug performance and patient compliance. Our proven methods and technologies provide our customers with unique and measurable technical and competitive advantages.



Management Team

The BioPharmX management team consists of Silicon Valley executives, scientists and business professionals combining large company discipline with deep biotech expertise focused on drug delivery and molecular properties. The team has the proven ability to raise capital and streamline new technologies into viable, marketable and successful products.



Jim Pekarsky                                                                                                                          

Mr. Pekarsky has devoted over 30 years to growing diverse medical research and high-tech companies, including Bio Rad Laboratories, Mentor Graphics, MoSys and Virage Logic. He has spent over 10 years as the Chief Financial Officer of several public and private companies and five years as a European General Manager for U.S. multinational corporations. For more than a decade he has been counseling start-ups in Silicon Valley and leading their financings, acquisitions and initial public offerings. Pekarsky holds an M.B.A. in finance from Golden Gate University in San Francisco and a bachelor’s degree in accounting from Indiana University of Pennsylvania.


Anja Krammer                                                                                                                                    

A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.

Kin F. Chan, Ph.D.                                                                                                                             

Dr. Chan is a serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions. His research and product development experience spans semiconductors, lasers/photonics, medical devices and biomedical sciences. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology. Prior to BiopharmX, Chan was Vice President of Engineering at Demira, where he helped develop photodynamic therapies and directed advanced research at Solta Medical, where he helped create fractional photothermolysis technology. He is a co-inventor on more than 25 patents and pending patent applications. Chan holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.

Douglas Thomas, Ph.D.                                                                                                                     

Dr. Thomas has more than 20 years of experience in biopharmaceutical research, process development, manufacturing and commercial development in start-ups and Fortune 500 companies. His background includes 10 years in business development and more than 10 years in research and development. He has consulted extensively in innovative start-ups focused on the application of diverse hardware and software in the biopharmaceutical industry. He has worked with a variety of biomedical companies, including BioSys Laboratories, Calypte Biomedical, Millipore and Invitrogen Life Technologies. Thomas holds a Ph.D. in immunology from Baylor College of Medicine and a bachelor’s degree in pharmacology from the University of California, Santa Barbara.

Jack Kessler, Ph.D.                                                                                                                           

Dr. Kessler has more than 35 years of applied development experience in the area of iodine-based formulations, bio-analytical assays, in vitro diagnostic (IVD) medical devices and regulatory affairs. He is a named inventor on more than 20 U.S. patents for analytical assays, IVD medical devices, iodine-based disinfectants and formulations and pharmaceutical dosage forms. Kessler has also authored more than 20 publications and book chapters and participated on six federal research grants from the National Institute of Health and the U.S. Department of Agriculture. He received a doctorate in biochemistry from SUNY at Syracuse and a bachelor’s degree in chemistry from Stevens Institute of Technology in New Jersey.

AnnaMarie Daniels                                                                                                                             

Ms. Daniels is a microbiologist and biochemist by training and holds multiple patents. She has authored or contributed to dozens of peer reviewed articles and abstracts on subjects ranging from in vitro assays to breast cancer prevention. For the last 35 years she has held technical and executive level positions in start-up and development stage pharmaceutical and medical device companies working in the areas of implantable biomaterials, oncology, women’s health, pain, urology and interventional neuroradiology. She has been responsible for all aspects of company operations and has specific expertise in design and implementation of clinical and regulatory strategy for new product development. Prior to joining BioPharmX, she led the botulinum neurotoxin program at Johnson & Johnson, the clinical research program for Boston Scientific Neuromodulation and served as an independent consultant for a number of pharmaceutical and medical device companies.

Ross Portaro                                                                                                                                     

Mr. Portaro has 30 years of global sales executive experience in dermatology, women's health, and aesthetics. In dermatology, most recently as a sales director at Ulthera, he doubled sales and positioned them for their 2014 acquisition by Merz. At Medicis, Portaro led the LipoSonix team in Europe and facilitated the sale to Solta in 2011. In Women's Health, he built the original sales team at SenoRx, which was the leader in breast biopsies devices and had a successful 2007 IPO. In aesthetics, Mr. Portaro started TRIA Beauty as the Vice President of Sales and was the first medical laser executive to globally launch a medical-grade laser for hair removal into the consumer OTC Market. TRIA Beauty is positioned for a 2014 IPO. Mr. Portaro received his BS in Commerce from the McIntyre School of Commerce at the University of Virginia.
Stephen Morlock                                                                                                                                    
A seasoned financial executive and retail industry veteran, has been added to its board of directors.  Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.

Morlock previously served as executive vice president and chief financial officer from 1994 to 2004 at Otis Spunkmeyer, a baked goods distribution company that has successfully pursued distribution of its products to small family-owned businesses all the way up to large worldwide organizations, including the U.S. Army.  He served as controller there from 1992 to 1994.  He also has experience garnered from these roles in various aspects of the retail industry, including going to market via various distribution channels, product merchandizing, customer relationship management, brand development, manufacturing, procurement, and inventory management.   

"Stephen brings a unique blend of financial expertise and experience in the retail industry to BioPharmX," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX Corporation.  "His expertise and experience will prove valuable as we continue retail distribution expansion for Violet iodine."

Prior to his roles at Otis Spunkmeyer, Morlock held various management positions in accounting, financial planning and internal auditing at Westinghouse Electric Supply Company from 1977 to 1991. He holds a B.S. degree in Accounting from San Diego State University


Corporate Headquarters

BioPharmX, Inc.
1098 Hamilton Court
Menlo Park, CA 94025

SEC Filings link below.

OneMed San Francisco 2014 Webcast

2015 Second Quater Finacial Results Webcast






  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: BioPharmX Announces Closing of $5.0 Million Offering 04/28/2017 04:15:00 PM
#483  Sticky Note BioPharmX Announces $5.0 Million Offering Whos_Who 04/26/17 09:06:37 AM
#522   Now that they have closed the offering, hopefully Dubb10 04/29/17 11:49:50 AM
#521   * * $BPMX Video Chart 04-28-17 * * ClayTrader 04/28/17 04:11:54 PM
#520   You're funny dude. Migs123 04/28/17 04:04:03 PM
#519   Price keeps going up??? Gimme_the_fibbers 04/28/17 03:13:45 PM
#518   Please excuse them. Thanks for your analysis Makin Millions 04/28/17 02:41:12 PM
#517   Agreed, this is a GEM. Gimme_the_fibbers 04/28/17 10:23:43 AM
#516   idk why people deny that charts show the Makin Millions 04/28/17 10:22:28 AM
#515   past performance does not play on this TRACING 04/28/17 10:19:01 AM
#514   lol why are you hating on Clay? he Makin Millions 04/28/17 10:12:11 AM
#513   Negative. Enjoy the cheap shares. Everyone knows this Migs123 04/28/17 09:57:10 AM
#512   Lie. ClayTrader 04/28/17 09:54:45 AM
#511   Claytrade is long BPMX $$$$$$$$$$$$ Gimme_the_fibbers 04/28/17 09:52:11 AM
#509   We are in the taco-supremo deluxe loading zone. Gimme_the_fibbers 04/28/17 09:49:29 AM
#508   * * $BPMX Video Chart 04-27-17 * * ClayTrader 04/27/17 05:15:53 PM
#507   Nice finish today! Looks like we're back on Whos_Who 04/27/17 04:33:01 PM
#506   just remember. this is a reipo not a Makin Millions 04/27/17 01:24:39 PM
#505   Wow! What a run! I was sick to SaltCityPunch 04/27/17 01:16:22 PM
#504   hahah its all good. Ive been in reipo's Makin Millions 04/27/17 12:58:02 PM
#503   You are absolutely correct!! My dumb ass meant Whos_Who 04/27/17 12:50:51 PM
#502   Re-reading my post, I friggen typed the wrong Whos_Who 04/27/17 12:46:19 PM
#501   good work. free shares Makin Millions 04/27/17 12:29:45 PM
#500   catch the run-up today because the market gave Makin Millions 04/27/17 12:28:36 PM
#499   no.. its an overreaction by the holders.. if Makin Millions 04/27/17 12:24:39 PM
#498   So who all sold yesterday? I told you Makin Millions 04/27/17 12:22:12 PM
#497   important positive news TRACING 04/27/17 08:27:08 AM
#496   Food for thought TRACING 04/27/17 01:44:47 AM
#495   topline phase 2b data could be released as TRACING 04/27/17 01:42:59 AM
#494   This is how they fund their operations, they TRACING 04/27/17 01:40:03 AM
#493   Maybe the deal would not have happened then. Whos_Who 04/26/17 12:47:25 PM
#492   If so, why not wait a few weeks Cre8tivmynd 04/26/17 11:57:38 AM
#491   Just picked up more at .70 SaltCityPunch 04/26/17 11:45:34 AM
#490   IMO, P2B data results are going to be Whos_Who 04/26/17 11:45:29 AM
#489   Good news for the long term IMO pennyroller16 04/26/17 11:35:50 AM
#488   If your business was approached by existing institutional Whos_Who 04/26/17 11:30:52 AM
#487   What are your guy's thoughts on the 2b SaltCityPunch 04/26/17 10:50:41 AM
#486   Youre giving your shares away if you sell Makin Millions 04/26/17 09:47:01 AM
#485   This CEO flat out lied when she said JenningsB 04/26/17 09:36:12 AM
#484   didnt see an offering coming at these prices Tdash 04/26/17 09:21:17 AM
#483   BioPharmX Announces $5.0 Million Offering Whos_Who 04/26/17 09:06:37 AM
#482   They said in the earning conference call that Dubb10 04/25/17 03:52:47 AM
#481   Yea I believe so but U never know Tdash 04/24/17 11:29:56 AM
#480   No RS needed over one dollar this week Jessearroyo8 04/24/17 10:58:17 AM
#479   Its official. we good here as long as Tdash 04/24/17 10:41:00 AM
#478   I told you so... BPMX was/is OFFICIAL Gimme_the_fibbers 04/24/17 10:34:39 AM
#477   Its on its Wayyyyy Tdash 04/24/17 10:21:46 AM
#476   BPMX - Securities Registration: Employee Benefit Plan (s-8) pennyroller16 04/21/17 05:16:53 PM
#475   BPMX - Annual Report (10-k) pennyroller16 04/21/17 05:08:49 PM
#474   Looking great! Migs123 04/21/17 12:37:28 PM
#473   The run has started! The GOLDEN CROSS!! over Jessearroyo8 04/21/17 12:12:30 PM
#472   BioPharmX Completes Last Subject Visit in its Phase Whos_Who 04/20/17 09:38:52 AM